Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients.

Quinn JA, Bennett L, Patel M, Frixou M, Park JH, Roseweir A, Horgan PG, McMillan DC, Edwards J.

Histol Histopathol. 2019 Oct 8:18168. doi: 10.14670/HH-18-168. [Epub ahead of print]

PMID:
31592535
2.

An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19.

Shaw VS, Mohammadi M, Quinn JA, Vashisth H, Neubig RR.

Mol Pharmacol. 2019 Dec;96(6):683-691. doi: 10.1124/mol.119.117176. Epub 2019 Sep 22.

PMID:
31543506
3.

Supporting a Healthy Microbiome for the Primary Prevention of Eczema.

Szari S, Quinn JA.

Clin Rev Allergy Immunol. 2019 Oct;57(2):286-293. doi: 10.1007/s12016-019-08758-5. Review.

PMID:
31309394
4.

The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer.

Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, Horgan PG, McMillan DC, Park JH, Edwards J.

Int J Cancer. 2019 May 1;144(9):2320-2329. doi: 10.1002/ijc.32045. Epub 2019 Jan 11.

PMID:
30521130
5.

Humanitarian applications of machine learning with remote-sensing data: review and case study in refugee settlement mapping.

Quinn JA, Nyhan MM, Navarro C, Coluccia D, Bromley L, Luengo-Oroz M.

Philos Trans A Math Phys Eng Sci. 2018 Sep 13;376(2128). pii: 20170363. doi: 10.1098/rsta.2017.0363.

6.

Adverse Events in Hospitalized Pediatric Patients.

Stockwell DC, Landrigan CP, Toomey SL, Loren SS, Jang J, Quinn JA, Ashrafzadeh S, Wang MJ, Wu M, Sharek PJ, Classen DC, Srivastava R, Parry G, Schuster MA; GAPPS Study Group.

Pediatrics. 2018 Aug;142(2). pii: e20173360. doi: 10.1542/peds.2017-3360. Epub 2018 Jul 13.

7.

Care Quality and Spending Among Commercially Insured Children With Disabilities.

Chien AT, Toomey SL, Kuo DZ, Van Cleave J, Houtrow AJ, Okumura MJ, Westfall MY, Petty CR, Quinn JA, Kuhlthau KA, Schuster MA.

Acad Pediatr. 2019 Apr;19(3):291-299. doi: 10.1016/j.acap.2018.06.004. Epub 2018 Jun 19.

PMID:
29932986
8.

Quality of Primary Care for Children With Disabilities Enrolled in Medicaid.

Chien AT, Kuhlthau KA, Toomey SL, Quinn JA, Okumura MJ, Kuo DZ, Houtrow AJ, Van Cleave J, Landrum MB, Jang J, Janmey I, Furdyna MJ, Schuster MA.

Acad Pediatr. 2017 May - Jun;17(4):443-449. doi: 10.1016/j.acap.2016.10.015. Epub 2017 Mar 9.

PMID:
28286057
9.

Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data.

Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, Nunes T, Pye S, Watson W, Ramos AA, Cordero JF, Huang WT, Kochhar S, Buttery J; Brighton Collaboration Preterm Birth Working Group.

Vaccine. 2016 Dec 1;34(49):6047-6056. doi: 10.1016/j.vaccine.2016.03.045. Epub 2016 Oct 13.

10.

Performance of the Global Assessment of Pediatric Patient Safety (GAPPS) Tool.

Landrigan CP, Stockwell D, Toomey SL, Loren S, Tracy M, Jang J, Quinn JA, Ashrafzadeh S, Wang M, Sharek PJ, Parry G, Schuster MA.

Pediatrics. 2016 Jun;137(6). pii: e20154076. doi: 10.1542/peds.2015-4076.

11.

Development of the Children With Disabilities Algorithm.

Chien AT, Kuhlthau KA, Toomey SL, Quinn JA, Houtrow AJ, Kuo DZ, Okumura MJ, Van Cleave JM, Johnson CK, Mahoney LL, Martin J, Landrum MB, Schuster MA.

Pediatrics. 2015 Oct;136(4):e871-8. doi: 10.1542/peds.2015-0228.

12.
13.

Bacillus Calmette-Guérin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system.

Clothier HJ, Hosking L, Crawford NW, Russell M, Easton ML, Quinn JA, Buttery JP.

Drug Saf. 2015 Jan;38(1):79-86. doi: 10.1007/s40264-014-0248-6.

PMID:
25475539
14.

The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.

Magruder HT, Quinn JA, Schwartzbauer JE, Reichner J, Huang A, Filardo EJ.

Horm Cancer. 2014 Dec;5(6):390-404. doi: 10.1007/s12672-014-0195-9. Epub 2014 Aug 6.

15.

Direct learning of sparse changes in Markov networks by density ratio estimation.

Liu S, Quinn JA, Gutmann MU, Suzuki T, Sugiyama M.

Neural Comput. 2014 Jun;26(6):1169-97. doi: 10.1162/NECO_a_00589. Epub 2014 Mar 31.

PMID:
24684449
16.

PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition.

Macdonald FH, Yao D, Quinn JA, Greenhalgh DA.

Oncogene. 2014 Aug 7;33(32):4132-43. doi: 10.1038/onc.2013.372. Epub 2013 Sep 16.

PMID:
24037529
17.

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE 2nd, McLendon RE, Friedman HS.

J Neurooncol. 2013 Aug;114(1):135-40. doi: 10.1007/s11060-013-1162-y. Epub 2013 May 18.

PMID:
23686298
18.

Generalized anisotropic stratified surface sampling.

Quinn JA, Langbein FC, Lai YK, Martin RR.

IEEE Trans Vis Comput Graph. 2013 Jul;19(7):1143-57. doi: 10.1109/TVCG.2012.305.

PMID:
23661009
19.

Clinical trial discussion, referral, and recruitment: physician, patient, and system factors.

Kaplan CP, Nápoles AM, Dohan D, Shelley Hwang E, Melisko M, Nickleach D, Quinn JA, Haas J.

Cancer Causes Control. 2013 May;24(5):979-88. doi: 10.1007/s10552-013-0173-5. Epub 2013 Feb 19.

PMID:
23420328
20.

Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context.

Timpson P, McGhee EJ, Erami Z, Nobis M, Quinn JA, Edward M, Anderson KI.

J Vis Exp. 2011 Oct 13;(56):e3089. doi: 10.3791/3089.

21.

Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway.

Cheng SB, Quinn JA, Graeber CT, Filardo EJ.

J Biol Chem. 2011 Jun 24;286(25):22441-55. doi: 10.1074/jbc.M111.224071. Epub 2011 May 2.

22.

Keratinocytes stimulate fibroblast hyaluronan synthesis through the release of stratifin: a possible role in the suppression of scar tissue formation.

Edward M, Quinn JA, Sands W.

Wound Repair Regen. 2011 May-Jun;19(3):379-86. doi: 10.1111/j.1524-475X.2011.00678.x. Epub 2011 Apr 21.

PMID:
21518083
23.

Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus.

Cheng SB, Graeber CT, Quinn JA, Filardo EJ.

Steroids. 2011 Aug;76(9):892-6. doi: 10.1016/j.steroids.2011.02.018. Epub 2011 Feb 25.

PMID:
21354433
24.

Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M, Olson MF, Frame MC, Brunton VG, Sansom OJ, Anderson KI.

Cancer Res. 2011 Feb 1;71(3):747-57. doi: 10.1158/0008-5472.CAN-10-2267. Epub 2011 Jan 25.

25.

Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.

Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG.

Radiology. 2010 Sep;256(3):735-43. doi: 10.1148/radiol.10091131. Epub 2010 Jul 27.

PMID:
20663970
26.

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk.

Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, Quinn JA, Edward M, Meehan RR, Evans EE, Langdon SP, Harrison DJ.

Br J Cancer. 2010 Jul 27;103(3):401-10. doi: 10.1038/sj.bjc.6605763. Epub 2010 Jul 13.

27.

4-Methylumbelliferone inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors.

Edward M, Quinn JA, Pasonen-Seppänen SM, McCann BA, Tammi RH.

Br J Dermatol. 2010 Jun;162(6):1224-32. doi: 10.1111/j.1365-2133.2010.09699.x. Epub 2010 Feb 15.

PMID:
20163414
28.

Factorial switching linear dynamical systems applied to physiological condition monitoring.

Quinn JA, Williams CK, McIntosh N.

IEEE Trans Pattern Anal Mach Intell. 2009 Sep;31(9):1537-51. doi: 10.1109/TPAMI.2008.191.

PMID:
19574617
29.

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS.

J Neurooncol. 2009 Dec;95(3):393-400. doi: 10.1007/s11060-009-9937-x. Epub 2009 Jun 17.

30.

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS.

Cancer. 2009 Jul 1;115(13):2964-70. doi: 10.1002/cncr.24336.

31.

Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30.

Quinn JA, Graeber CT, Frackelton AR Jr, Kim M, Schwarzbauer JE, Filardo EJ.

Mol Endocrinol. 2009 Jul;23(7):1052-64. doi: 10.1210/me.2008-0262. Epub 2009 Apr 2.

32.

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE Jr, Walker A, Friedman HS.

Neuro Oncol. 2009 Oct;11(5):556-61. doi: 10.1215/15228517-2009-007. Epub 2009 Mar 16.

33.

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS.

J Clin Oncol. 2009 Mar 10;27(8):1262-7. doi: 10.1200/JCO.2008.18.8417. Epub 2009 Feb 9.

34.

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Threatt S, Friedman HS.

Clin Cancer Res. 2009 Feb 1;15(3):1064-8. doi: 10.1158/1078-0432.CCR-08-2130.

35.

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.

Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260.

36.

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.

Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS.

Neuro Oncol. 2008 Oct;10(5):745-51. doi: 10.1215/15228517-2008-044. Epub 2008 Aug 28.

37.

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS.

Clin Cancer Res. 2008 Aug 1;14(15):4859-68. doi: 10.1158/1078-0432.CCR-07-4807.

38.

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS.

Ther Clin Risk Manag. 2007 Oct;3(5):707-15.

39.

Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity.

Yao D, Alexander CL, Quinn JA, Chan WC, Wu H, Greenhalgh DA.

J Cell Sci. 2008 May 15;121(Pt 10):1758-69. doi: 10.1242/jcs.021147. Epub 2008 Apr 29.

40.

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS.

Neuro Oncol. 2008 Jun;10(3):330-40. doi: 10.1215/15228517-2008-003. Epub 2008 Mar 21.

41.

Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor.

Filardo EJ, Quinn JA, Sabo E.

Steroids. 2008 Oct;73(9-10):870-3. doi: 10.1016/j.steroids.2007.12.025. Epub 2008 Jan 3. Review.

PMID:
18289622
42.

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD.

Neuro Oncol. 2008 Apr;10(2):182-9. doi: 10.1215/15228517-2007-053. Epub 2008 Feb 20.

43.

Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.

Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD.

J Pathol. 2008 Apr;214(5):584-93. doi: 10.1002/path.2311. Erratum in: J Pathol. 2008 aPR;214(5):593.

PMID:
18220317
44.

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

J Clin Oncol. 2007 Oct 20;25(30):4722-9.

PMID:
17947719
45.

Molecularly targeted therapy for malignant glioma.

Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN.

Cancer. 2007 Jul 1;110(1):13-24. Review.

46.

Temozolomide in children with progressive low-grade glioma.

Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS.

Neuro Oncol. 2007 Apr;9(2):161-8. Epub 2007 Mar 8.

47.

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.

Clin Cancer Res. 2007 Feb 15;13(4):1253-9.

48.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA.

J Neurooncol. 2007 May;83(1):53-60. Epub 2007 Jan 24.

PMID:
17245623
49.

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ.

Neuro Oncol. 2007 Jan;9(1):70-4. Epub 2006 Nov 15.

50.

Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E.

Clin Cancer Res. 2006 Nov 1;12(21):6359-66.

Supplemental Content

Loading ...
Support Center